SG154333A1 - The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases - Google Patents
The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseasesInfo
- Publication number
- SG154333A1 SG154333A1 SG200608456-0A SG2006084560A SG154333A1 SG 154333 A1 SG154333 A1 SG 154333A1 SG 2006084560 A SG2006084560 A SG 2006084560A SG 154333 A1 SG154333 A1 SG 154333A1
- Authority
- SG
- Singapore
- Prior art keywords
- preparations containing
- associated diseases
- treating hyperlipidemia
- combination preparations
- substituted
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38522002P | 2002-06-03 | 2002-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG154333A1 true SG154333A1 (en) | 2009-08-28 |
Family
ID=29712145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200608456-0A SG154333A1 (en) | 2002-06-03 | 2003-06-02 | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20050176806A1 (https=) |
| EP (1) | EP1513519B1 (https=) |
| JP (2) | JP2005532338A (https=) |
| KR (1) | KR20050012771A (https=) |
| CN (2) | CN100402026C (https=) |
| AT (1) | ATE422884T1 (https=) |
| AU (2) | AU2003245903B2 (https=) |
| BR (1) | BR0311535A (https=) |
| CA (1) | CA2487297C (https=) |
| CY (1) | CY1112800T1 (https=) |
| DE (1) | DE60326232D1 (https=) |
| DK (1) | DK1513519T3 (https=) |
| EC (1) | ECSP045469A (https=) |
| ES (1) | ES2321600T3 (https=) |
| IL (1) | IL165181A (https=) |
| MX (1) | MXPA04012149A (https=) |
| NO (1) | NO333585B1 (https=) |
| NZ (1) | NZ536832A (https=) |
| PL (1) | PL210408B1 (https=) |
| PT (1) | PT1513519E (https=) |
| RU (1) | RU2362555C2 (https=) |
| SG (1) | SG154333A1 (https=) |
| SI (1) | SI1513519T1 (https=) |
| WO (1) | WO2003101448A1 (https=) |
| ZA (1) | ZA200409136B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| DK1715893T3 (da) | 2004-01-20 | 2009-11-09 | Novartis Pharma Ag | Direkte kompressionsformulering og fremgangsmåde |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
| AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| US20100260841A1 (en) * | 2007-02-08 | 2010-10-14 | Paolini John F | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| KR20210143848A (ko) * | 2019-03-22 | 2021-11-29 | 러쉬 유니버시티 메디컬 센터 | 리소좀 축적 장애를 위한 비강 유전자 전달 및 경구 신남산, 올레아미드 또는 젬피브로질의 병용 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0187052A1 (fr) * | 1984-10-31 | 1986-07-09 | S.A. PANMEDICA Société dite: | Nouveaux dérivés de l'adamantanamine, leurs procédés de préparation et médicaments les contenant |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
| EP1125922A1 (en) * | 1998-11-02 | 2001-08-22 | Welfide Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| WO2003038123A2 (en) * | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW222626B (https=) * | 1991-07-22 | 1994-04-21 | Pfizer | |
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| AU766219B2 (en) * | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| JP4232332B2 (ja) * | 1999-11-10 | 2009-03-04 | 末藏 岩田 | タンク付電動床磨機用ブラシ台 |
| PT1741446E (pt) * | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| TW200810743A (en) * | 2002-03-22 | 2008-03-01 | Novartis Ag | Combination of organic compounds |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| WO2005117861A1 (en) * | 2004-06-04 | 2005-12-15 | Novartis Ag | Use of organic compounds |
| CA2622579C (en) * | 2005-09-20 | 2013-12-31 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
-
2003
- 2003-06-02 CN CNB038128446A patent/CN100402026C/zh not_active Expired - Fee Related
- 2003-06-02 CA CA2487297A patent/CA2487297C/en not_active Expired - Fee Related
- 2003-06-02 NZ NZ536832A patent/NZ536832A/en not_active IP Right Cessation
- 2003-06-02 MX MXPA04012149A patent/MXPA04012149A/es active IP Right Grant
- 2003-06-02 RU RU2004139029/14A patent/RU2362555C2/ru not_active IP Right Cessation
- 2003-06-02 JP JP2004508806A patent/JP2005532338A/ja not_active Withdrawn
- 2003-06-02 AU AU2003245903A patent/AU2003245903B2/en not_active Ceased
- 2003-06-02 PT PT03737984T patent/PT1513519E/pt unknown
- 2003-06-02 ES ES03737984T patent/ES2321600T3/es not_active Expired - Lifetime
- 2003-06-02 SG SG200608456-0A patent/SG154333A1/en unknown
- 2003-06-02 PL PL374016A patent/PL210408B1/pl not_active IP Right Cessation
- 2003-06-02 EP EP03737984A patent/EP1513519B1/en not_active Expired - Lifetime
- 2003-06-02 US US10/516,633 patent/US20050176806A1/en not_active Abandoned
- 2003-06-02 DK DK03737984T patent/DK1513519T3/da active
- 2003-06-02 CN CNA2008100965659A patent/CN101273987A/zh active Pending
- 2003-06-02 SI SI200331571T patent/SI1513519T1/sl unknown
- 2003-06-02 BR BR0311535-6A patent/BR0311535A/pt not_active IP Right Cessation
- 2003-06-02 KR KR10-2004-7019595A patent/KR20050012771A/ko not_active Ceased
- 2003-06-02 AT AT03737984T patent/ATE422884T1/de active
- 2003-06-02 DE DE60326232T patent/DE60326232D1/de not_active Expired - Lifetime
- 2003-06-02 WO PCT/EP2003/005762 patent/WO2003101448A1/en not_active Ceased
-
2004
- 2004-11-11 IL IL165181A patent/IL165181A/en not_active IP Right Cessation
- 2004-11-11 ZA ZA2004/09136A patent/ZA200409136B/en unknown
- 2004-12-01 EC EC2004005469A patent/ECSP045469A/es unknown
- 2004-12-14 NO NO20045452A patent/NO333585B1/no not_active IP Right Cessation
-
2006
- 2006-11-30 AU AU2006246483A patent/AU2006246483B9/en not_active Ceased
-
2009
- 2009-05-11 CY CY20091100499T patent/CY1112800T1/el unknown
-
2010
- 2010-04-05 JP JP2010087181A patent/JP2010155866A/ja active Pending
-
2011
- 2011-09-26 US US13/245,226 patent/US20120014907A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0187052A1 (fr) * | 1984-10-31 | 1986-07-09 | S.A. PANMEDICA Société dite: | Nouveaux dérivés de l'adamantanamine, leurs procédés de préparation et médicaments les contenant |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| EP1125922A1 (en) * | 1998-11-02 | 2001-08-22 | Welfide Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
| US6166063A (en) * | 1998-12-10 | 2000-12-26 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| WO2003038123A2 (en) * | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG154333A1 (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| SE0104340D0 (sv) | New compounds | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| ES2165969T3 (es) | Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios. | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| ATE448199T1 (de) | Verbindungen mit taxol-verstärkender wirkung | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| IL127965A0 (en) | Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| WO2002089782A3 (en) | Dioxanes and uses thereof | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| AP1564A (en) | Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use. | |
| AR002018A1 (es) | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y | |
| RU94038256A (ru) | Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе | |
| SE0102440D0 (sv) | New compound | |
| MXPA05013607A (es) | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. | |
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
| HUT55034A (en) | Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient | |
| MXPA04000485A (es) | Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa. | |
| EP1325918A4 (en) | INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE | |
| TW200517367A (en) | Improved pharmaceutical drug candidates and methods for preparation thereof | |
| PL370379A1 (pl) | N-Tlenek prukaloprydu, sposób jego wytwarzania i zastosowanie oraz zawierająca go kompozycja i sposób jej wytwarzania | |
| DE69904025D1 (de) | Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen |